4-IPP
Based on 11 publication(s) in Google Scholar
4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.40%
- CAS No.: 41270-96-6
- Formule: C10H7IN2
- Masse moléculaire:282.08
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Covalent Screening Library
HY-L036
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Macrophage Related Compound Library
HY-L174
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Immunology/Inflammation Compound Library
HY-L007
Publications Citing Use of MedChemExpress (MCE) 4-IPP
More- Mol Neurodegener. 2025 May 31;20(1):62. [Abstract]
- Theranostics. 2023 Aug 18;13(13):4574-4600. [Abstract]
- J Clin Invest. 2025 Dec 15;135(24):e193082. [Abstract]
- J Exp Clin Cancer Res. 2025 Jan 31;44(1):33. [Abstract]
- Environ Sci Technol. 2025 Mar 11;59(9):4530-4539. [Abstract]
- NPJ Precis Oncol. 2025 Aug 20;9(1):293. [Abstract]
- Leukemia. 2025 Aug 1. [Abstract]
- Neural Regen Res. 2023 Aug;18(8):1802-1808. [Abstract]
- Clin Transl Med. 2024 Aug;14(8):e1786. [Abstract]
- Bone. 2025 Jan:190:117331. [Abstract]
- Res Sq. 2026 Mar 13.
Customer Validation & Images
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
Flow Cytometry
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
Activité biologique
MIF[1]
4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity[1].
4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes[1].
4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation[1].
4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner[1].
4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BMMs
-
Concentration:0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM
-
Incubation Time:24 hours, 72 hours
-
Result:Inhibited osteoclastogenesis in a dose-dependent manner.
-
Cell Line:BMMs
-
Concentration:5 μM,10 μM, 20 μM
-
Incubation Time:1 day, 3 days, 5 days
-
Result:Inhibited RANKL-induced osteoclast differentiation and bone resorption.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8-weeks-old C57BL/6J male mice[1]
-
Dosage:1 mg/kg, 5 mg/kg
-
Administration:Intraperitoneal injection; every 2 days; for 8 weeks
-
Result:Alleviated OVX-induced osteoporosis.
Chemical Information
-
CAS No. 41270-96-6
-
Appearance Solid
-
Masse moléculaire 282.08
-
Formule C10H7IN2
-
Color White to yellow
-
SMILES
IC1=CC(C2=CC=CC=C2)=NC=N1
-
Synonyms
4-Iodo-6-phenylpyrimidine
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Mol Neurodegener
Early transcriptional and cellular abnormalities in choroid plexus of a mouse model of Alzheimer's disease. [Abstract]2025 May 31;20(1):62. PMID: 40450296 -
Theranostics
Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer. [Abstract]2023 Aug 18;13(13):4574-4600. PMID: 37649598
4-IPP purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Aug 18;13(13):4574-4600. [Abstract]
4-IPP (80 mg/kg, intraperitoneal therapy). MIF inhibitors significantly inhibited the growth of gastric cancer.
4-IPP purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Aug 18;13(13):4574-4600. [Abstract]
4-IPP (80 mg/kg, intraperitoneal therapy). Immunofluorescence revealed the infiltration level of T cells in the MIF-inhibited group and the control group.
4-IPP purchased from MedChemExpress. Usage Cited in: Theranostics. 2023 Aug 18;13(13):4574-4600. [Abstract]
4-IPP (80 mg/kg, intraperitoneal therapy). Flow cytometry was used to analyze the proportion and cytotoxicity of CD4+ T cells in the MIF inhibitor and control groups.
-
J Clin Invest
Leukemia-expanded splenic CD81+ erythroblasts potentiate disease progression in mice by reshaping leukemic cell metabolism. [Abstract]2025 Dec 15;135(24):e193082. PMID: 41392984
4-IPP purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2025 Dec 15;135(24):e193082. [Abstract]
Illustration of experimental design (top) and cell counts (bottom) of AML cells cocultured with CD81+ Erys pretreated with either 10 μM 4-IPP or DMSO (n = 5).
-
J Exp Clin Cancer Res
Myeloid cell-derived apCAFs promote HNSCC progression by regulating proportion of CD4+ and CD8+ T cells. [Abstract]2025 Jan 31;44(1):33. PMID: 39891284
4-IPP purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Jan 31;44(1):33. [Abstract]
4-IPP (5 mg/kg, IP, every 2 days for 15 days). In vivo, inhibition of MIF and p-STAT3 can reduce tumor size.
4-IPP purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Jan 31;44(1):33. [Abstract]
4-IPP (5 mg/kg, IP, every 2 days for 15 days). Flow cytometry results demonstrate that inhibition of MIF and p-STAT3 decrease the number of CD74+ PDGFRB+ cells.
-
Environ Sci Technol
IodoFinder: Machine Learning-Guided Recognition of Iodinated Chemicals in Nontargeted LC-MS/MS Analysis. [Abstract]2025 Mar 11;59(9):4530-4539. PMID: 40015982 -
NPJ Precis Oncol
Single-cell transcriptome analysis identifies MIF as a novel tumor-associated neutrophil marker for pancreatic ductal adenocarcinoma. [Abstract]2025 Aug 20;9(1):293. PMID: 40835726 -
Leukemia
The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma. [Abstract]2025 Aug 1. PMID: 40750676
4-IPP purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Aug 1. [Abstract]
BMMCs were treated with Dara ± inhibitors (Belimumab [BAFF], 4-IPP [MIF], and MYCi975 [MYC]) for 24 h, then co-cultured with NK-cells at an effector:target (E:T) ratio = 1:1 for 12 h. The amount of released LDH was determined using a cytotoxicity assay kit to calculate the % of lysed cells.
-
Neural Regen Res
Macrophage migration inhibitory factor facilitates astrocytic production of the CCL2 chemokine following spinal cord injury. [Abstract]2023 Aug;18(8):1802-1808. PMID: 36751809 -
Clin Transl Med
Single-cell transcriptome analysis deciphers the CD74-mediated immune evasion and tumour growth in lung squamous cell carcinoma with chronic obstructive pulmonary disease. [Abstract]2024 Aug;14(8):e1786. PMID: 39113235 -
Bone
Macrophage migration inhibitory factor promotes heterotopic ossification by mediating ROS/HIF-1α positive feedback loop and activating Wnt/β-catenin signaling pathway. [Abstract]2025 Jan:190:117331. PMID: 39549900 -
Solvant et solubilité
DMSO : 100 mg/mL (354.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (476 KB)
- English - EN (476 KB)
- Français - FR (476 KB)
- Deutsch - DE (476 KB)
- Norwegian - NO (476 KB)
- Español - ES (476 KB)
- Swedish - SV (476 KB)
- Italian - IT (476 KB)
- Korean - KR (476 KB)
- Portuguese - PT (476 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5451 mL | 17.7255 mL | 35.4509 mL | 88.6273 mL |
| 5 mM | 0.7090 mL | 3.5451 mL | 7.0902 mL | 17.7255 mL | |
| 10 mM | 0.3545 mL | 1.7725 mL | 3.5451 mL | 8.8627 mL | |
| 15 mM | 0.2363 mL | 1.1817 mL | 2.3634 mL | 5.9085 mL | |
| 20 mM | 0.1773 mL | 0.8863 mL | 1.7725 mL | 4.4314 mL | |
| 25 mM | 0.1418 mL | 0.7090 mL | 1.4180 mL | 3.5451 mL | |
| 30 mM | 0.1182 mL | 0.5908 mL | 1.1817 mL | 2.9542 mL | |
| 40 mM | 0.0886 mL | 0.4431 mL | 0.8863 mL | 2.2157 mL | |
| 50 mM | 0.0709 mL | 0.3545 mL | 0.7090 mL | 1.7725 mL | |
| 60 mM | 0.0591 mL | 0.2954 mL | 0.5908 mL | 1.4771 mL | |
| 80 mM | 0.0443 mL | 0.2216 mL | 0.4431 mL | 1.1078 mL | |
| 100 mM | 0.0355 mL | 0.1773 mL | 0.3545 mL | 0.8863 mL |
4-IPP Related Classifications
HY-110063 Related Classifications
Powered by Bioz